In contrast, some other agents being tested as a treatment for NASH may increase serum levels of cholesterol, often requiring concomitant therapy with an HMG CoA Reductase inhibitor (a “statin”) (e.g., obeticholic acid)35. The gene discussed is HMGCR; the disease is metabolic dysfunction-associated steatohepatitis.